Trails Edge reports 8.06M IKT shares (6.1%)

Inhibikase Therapeutics ownership update: Trails Edge Biotechnology Master Fund reports beneficial ownership of 8,057,345 shares of Inhibikase Therapeutics common stock, representing 6.1% of the outstanding shares as of the Event Date March 31, 2026.

Rhea-AI Filing Summary

Inhibikase Therapeutics ownership update: Trails Edge Biotechnology Master Fund reports beneficial ownership of 8,057,345 shares of Inhibikase Therapeutics common stock, representing 6.1% of the outstanding shares as of the Event Date March 31, 2026. The filing states the 8,057,345 shares are held directly by Trails Edge Biotechnology and that Trails Edge Capital and Ortav Yehudai may be deemed to beneficially own the same shares due to management and voting discretion. The ownership percentage is calculated using 132,032,636 shares reported as issued and outstanding in the Issuer’s Annual Report on Form 10-K for the year ended December 31, 2025.

Insights

Portfolio Manager

Trails Edge discloses a 6.1% stake in Inhibikase (8,057,345 shares).

The filing lists 8,057,345 shares held directly by Trails Edge Biotechnology Master Fund as of March 31, 2026. Ownership percentage is computed using 132,032,636 shares outstanding from the issuer's Form 10-K for the year ended December 31, 2025.

Cash-flow treatment and planned transactions are not described; subsequent filings would show any purchases or disposals. The joint-filing agreement is referenced as Exhibit 1.

Securities Counsel

Disclosure aligns with Schedule 13G/A joint-filer rules and attributes beneficial ownership to manager and CIO.

The document states Trails Edge Capital is investment manager to Trails Edge Biotechnology and that Ortav Yehudai, as CIO, exercises voting and investment discretion. The filing is signed and includes a Joint Filing Agreement dated December 31, 2025.

The submission amends prior reporting; no regulatory enforcement or contested claims are disclosed. Any change in holdings would require new filings under applicable rules.

Key Figures

Beneficial ownership: 8,057,345 shares Percent of class: 6.1% Shares outstanding used: 132,032,636 shares

3 metrics

Beneficial ownership 8,057,345 shares As of March 31, 2026 (Event Date)

Percent of class 6.1% Calculated using 132,032,636 shares outstanding (Form 10-K, year ended December 31, 2025)

Shares outstanding used 132,032,636 shares Issuer's Annual Report on Form 10-K for year ended December 31, 2025 (filed March 26, 2026)

Key Terms

beneficially own, sole dispositive power, Joint Filing Agreement

3 terms

beneficially own regulatory

"As of March 31, 2026 (the "Event Date"), each Filer may be deemed to beneficially own an aggregate"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

sole dispositive power regulatory

"Sole Dispositive Power 8,057,345.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Joint Filing Agreement regulatory

"Exhibit 1 - Joint Filing Agreement, dated as of December 31, 2025"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Inhibikase (IKT) shares does Trails Edge report owning?

Trails Edge reports beneficial ownership of 8,057,345 shares. The filing states these shares are held directly by Trails Edge Biotechnology as of March 31, 2026, and the percentage uses 132,032,636 shares outstanding from the issuer's Form 10-K.

What percentage of IKT does the 8,057,345‑share position represent?

The stake represents 6.1% of Inhibikase's outstanding common stock. That percentage is calculated using the 132,032,636 shares reported as issued and outstanding in the company's Form 10-K for the year ended December 31, 2025.

Who are the filers named in the Schedule 13G/A for IKT?

The filers are Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai. Trails Edge Capital is the investment manager and Mr. Yehudai is identified as Chief Investment Officer in the filing.

Are the 8,057,345 shares held directly or indirectly according to the filing?

The filing states the 8,057,345 shares are held directly by Trails Edge Biotechnology Master Fund. Trails Edge Capital and Ortav Yehudai may be deemed beneficial owners due to management and voting discretion, per the disclosure.

Does the filing disclose any planned sales or purchases of IKT stock?

No—this Schedule 13G/A reports beneficial ownership and does not disclose planned purchases or sales. The filing references the joint-filing agreement and provides signatures but contains no transaction intentions or cash-flow instructions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 04:15 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Inhibikase Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

45719W205

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 45719W205

1

Names of Reporting Persons

Trails Edge Capital Partners, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 8,057,345.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 8,057,345.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,057,345.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.1 %

12

Type of Reporting Person (See Instructions)

IA, PN

Comment for Type of Reporting Person: See Item 4 for additional information.

SCHEDULE 13G

CUSIP Number(s): 45719W205

1

Names of Reporting Persons

Trails Edge Biotechnology Master Fund, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 8,057,345.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 8,057,345.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,057,345.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.1 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: See Item 4 for additional information.

SCHEDULE 13G

CUSIP Number(s): 45719W205

1

Names of Reporting Persons

Ortav Yehudai

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 8,057,345.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 8,057,345.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,057,345.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.1 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: See Item 4 for additional information.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Inhibikase Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 1000 N. West Street, Suite 1200
Item 2.
(a)	Name of person filing: This report on Schedule 13G/A (as amended, this "Schedule 13G") is being filed by Trails Edge Capital Partners, LP, a Delaware limited partnership ("Trails Edge Capital"), Trails Edge Biotechnology Master Fund, LP, a Cayman Islands limited partnership ("Trails Edge Biotechnology"), and Ortav Yehudai ("Mr. Yehudai"). Trails Edge Capital is the investment manager to Trails Edge Biotechnology, and Mr. Yehudai is the Chief Investment Officer of Trails Edge Capital. Each of Trails Edge Capital, Trails Edge Biotechnology and Mr. Yehudai are referred to individually as a "Filer" and collectively as the "Filers".
(b)	Address or principal business office or, if none, residence: The address for each Filer is 3455 Peachtree Road NE, 5th Floor, Atlanta, GA 30326.
(c)	Citizenship: See Item 4 of the cover page of each Filer.
(d)	Title of class of securities: Common Stock, $0.001 par value
(e)	CUSIP No.: 45719W205
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of March 31, 2026 (the "Event Date"), each Filer may be deemed to beneficially own an aggregate of 8,057,345 shares of Common Stock, par value $0.001 per share (the "Shares"), of Inhibikase Therapeutics, Inc. (the "Issuer"). The 8,057,345 Shares reported as beneficially owned on this Schedule 13G by each Filer consists of 8,057,345 Shares held directly by Trails Edge Biotechnology. As a result, Trails Edge Biotechnology beneficially owns 6.1% of the outstanding Shares of the Issuer as of the Event Date. Trails Edge Capital, as the investment manager to Trails Edge Biotechnology, may be deemed to beneficially own these securities. Mr. Yehudai, as the Chief Investment Officer of Trails Edge Capital, exercises voting and investment discretion with respect to these securities and as such may be deemed to beneficially own 6.1% of the outstanding Shares of the Issuer as of the Event Date. Ownership percentages are based on 132,032,636 Shares reported as issued and outstanding in the Issuer's Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission on March 26, 2026.
(b)	Percent of class: 6.1 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 8,057,345.00
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 8,057,345.00
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Trails Edge Capital Partners, LP

Signature:	Trails Edge Capital Partners, LLC, GP of Trails Edge Capital Partners, LP /s/ Ortav Yehudai
Name/Title:	Ortav Yehudai / Chief Investment Officer of Trails Edge Capital Partners, LLC
Date:	05/15/2026

Trails Edge Biotechnology Master Fund, LP

Signature:	Trails Edge GP, LLC, GP of Trails Edge Biotechnology Fund GP, LP, GP of Trails Edge Biotechnology Master Fund, LP /s/ Ortav Yehudai
Name/Title:	Ortav Yehudai / Chief Investment Officer of Trails Edge GP, LLC
Date:	05/15/2026

Ortav Yehudai

Signature:	/s/ Ortav Yehudai
Name/Title:	Ortav Yehudai / Individual
Date:	05/15/2026

Exhibit Information

Exhibit 1 - Joint Filing Agreement, dated as of December 31, 2025, by and between Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP and Ortav Yehudai (incorporated by reference to Exhibit 1 to the Schedule 13G filed with the Securities and Exchange Commission on December 31, 2025).